Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 1, 2012, Pages 96-105

  Antoń, Iker ^a   Molina, Eva ^a   Luis Ravelo, Diego ^a   Zandueta, Carolina ^a   Valencia, Karmele ^a   Ormazabal, Cristina ^a   Martińez Canarias, Susana ^a   Perurena, Naiara ^a   Pajares, María José ^a   Agorreta, Jackeline ^a   Montuenga, Luis M ^a   Segura, Victor ^a   Wistuba, Ignacio I ^b   De Las Rivas, Javier ^c   Hermida, José ^a   Lecanda, Fernando ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Adrenal gland; Bone metastasis; Microenvironment; Prognosis; Survival

Indexed keywords

ACTIVATED PROTEIN C; ENDOTHELIAL PROTEIN C RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOOD COAGULATION FACTORS; CELL SURVIVAL; CELLULAR MICROENVIRONMENT; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEIN C; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84863469949     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201110-1826OC     Document Type: Article

References (33)

1. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 1984;2:1352-1358. (Pubitemid 15179536)
2. Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer 1996;77:1947-1955. (Pubitemid 26125199)
3. Ginsberg RJKM, Armstrong JG. Non-small cell lung cancer. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
4. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer 2006;106:1624-1633.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
6. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet 2011;378:1727-1740.
7. Vicent S, Luis-Ravelo D, Anton I, Garcia-Tunon I, Borras-Cuesta F, Dotor J, De Las Rivas J, Lecanda F. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 2008;68:2275-2285. (Pubitemid 351521801)
8. Catena R, Luis-Ravelo D, Anton I, Zandueta C, Salazar-Colocho P, Larzabal L, Calvo A, Lecanda F. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res 2011;71:164-174.
9. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging NOTCH signaling in bone cells. Cancer Cell 2011;19:192-205.
10. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6:449-458.
11. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153:865-873. (Pubitemid 28419039)
12. Del Bufalo D, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 1997;11:947-953. (Pubitemid 27425896)
13. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J. Latent bone metastasis in breast cancer tied to src-dependent survival signals. Cancer Cell 2009;16:67-78.
14. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;32:49-60.
15. Feistritzer C, Sturn DH, Kaneider NC, Djanani A, Wiedermann CJ. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol 2003;112:375-381. (Pubitemid 36981379)
16. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-647. (Pubitemid 26030319)
17. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;104:3878-3885. (Pubitemid 39620133)
18. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:338-342. (Pubitemid 36362790)
19. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109:3161-3172. (Pubitemid 46572500)
20. Scheffer GL, Flens MJ, Hageman S, Izquierdo MA, Shoemaker RH, Scheper RJ. Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer 2002;38:1535-1542. (Pubitemid 34756407)
21. Tsuneyoshi N, Fukudome K, Horiguchi S, Ye X, Matsuzaki M, Toi M, Suzuki K, Kimoto M. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost 2001;85:356-361. (Pubitemid 32140584)
22. Beaulieu LM, Church FC. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res 2007;313:677-687. (Pubitemid 46198814)
23. Gramling MW, Beaulieu LM, Church FC. Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Exp Cell Res 2010;316:314-328.
24. Anton I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazábal C, Martínez-Canarias S, Pajares M-J, Agorreta J, Montuenga L, et al. APC/EPCR signaling promotes survival and bone metastasis in lung adenocarcinoma. Presented at the 11th International Conference on Cancer-Induced Bone Disease. November 30 - December 30, 2011, Chicago, IL. Abstract S36, p. 33.
25. Luis-Ravelo D, Anton I, Vicent S, Hernandez I, Valencia K, Zandueta C, Martinez-Canarias S, Gurpide A, Lecanda F. Tumor-stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clin Exp Metastasis 2011;28:779-791.
26. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J. Wnt/tcf signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009;138:51-62.
27. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGFR1-flt1 and VEGFR2-flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999;188:369-377. (Pubitemid 29327434)
28. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, Lopez-Picazo JM, Torre W, Pio R,Montuenga LM. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 2010;16:4113-4125.
29. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor vcam-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011;20:538-549.
30. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-770. (Pubitemid 46582040)
31. Valencia K, Ormazabal C, Zandueta C, Luis-Ravelo D, Anton I, Pajares MJ, Agorreta J, Montuenga LM, Martinez-Canarias S, Leitinger B, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res 2012;18:969-980.
32. Bezuhly M, Cullen R, Esmon CT, Morris SF, West KA, Johnston B, Liwski RS. Role of activated protein C and its receptor in inhibition of tumor metastasis. Blood 2009;113:3371-3374.
33. Van Sluis GL, Niers TM, Esmon CT, Tigchelaar W, Richel DJ, Buller HR, Van Noorden CJ, Spek CA. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 2009;114:1968-1973.